Corey Foster, MD
Cardiovascular Disease · Lake Charles, LANPI 1669693867
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,076 of the $157,946 with a category attached, or 62.7%. It is spread thinly across 50 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2019 at $52,423 and has fallen 98.1% since, to $977 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 705 payments — averaging $224.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$36K
- Penumbra, Inc.$34K
- Lilly USA, LLC$24K
- Shockwave Medical, Inc$19K
- Medtronic$12K
- Terumo Medical Corporation$8K
- plus $25K from 44 others
What the payments were for
- Consulting fees$8,1005%
- Speaking & faculty fees$99,07663%
- Travel & lodging$25,40416%
- Food & beverage$25,34716%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$58,727
- Indigo System$33,750
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$17,876
- COREVALVE EVOLUT R$9,135
- Vascepa$6,242
- GlideWire$5,600
- GLIDESHEATH SLENDER$5,600
- LifeVest$3,000
- Impella$1,935
- Watchman$1,062
- CoreValve Evolut$744
- Navicross$400
- R2P MISAGO$400
- TR Band$400
- METACROSS OTW$400
- Diamondback Peripheral$383
- Diamondback Coronary$335
- Vascular Lithotripsy$269
- OPTIMIZER$260
- FlowTriever$230
How this compares
$157,946 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 236 | $214,278 |
| XareltoRivaroxaban | 72 | $57,675 |
| EntrestoSacubitril/Valsartan | 63 | $53,029 |
| JardianceEmpagliflozin | 19 | $30,549 |
| FarxigaDapagliflozin Propanediol | 20 | $21,867 |
| BrilintaTicagrelor | 34 | $15,436 |
| Ranolazine ErRanolazine | 278 | $12,551 |
| Metoprolol Succinate | 254 | $3,613 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 294 | $3,444 |
| ClopidogrelClopidogrel Bisulfate | 329 | $3,188 |
| Atorvastatin Calcium | 239 | $2,068 |
| Rosuvastatin Calcium | 93 | $1,306 |
| Amlodipine Besylate | 227 | $1,173 |
| Metoprolol Tartrate | 172 | $1,060 |
| Furosemide | 288 | $999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $789 | $214,278236 claims |
| Johnson & JohnsonXarelto | $363 | $57,67572 claims |
| NovartisEntresto | $774 | $53,02963 claims |
| AstraZenecaFarxiga, Brilinta | $31 | $37,30354 claims |
| Boehringer IngelheimJardiance | $36,005 | $30,54919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lake Charles
- Richard GilmoreLake Charles$45K
- John WintertonLake Charles$15K
- Ahmad AwanLake Charles$13K
- Michael TurnerLake Charles$11K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.